Mein Warenkorb

B7-H5

B7-H5 Molekülinformation

Englischer NameV-domain Ig suppressor of T-cell activationAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel8Target-AliasDies1,VSIR,V-Set Domain-Containing Immunoregulatory Receptor,DD1alpha,B7-H5,PD-1H,B7H5,GI24,Stress-induced secreted protein-1,PP2135,SISP1,UNQ730/PRO1412,V-type immunoglobulin domain-containing suppressor of T-cell activation,V-Set Immunoregulatory Receptor,V-Domain Ig Suppressor Of T Cell Activation,PDCD1 Homolog,C10orf54,Sisp-1,VISTA,Chromosome 10 Open Reading Frame 54,Stress Induced Secreted Protein 1,Platelet Receptor Gi24,Death Domain1alpha
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Englischer NameV-domain Ig suppressor of T-cell activation
Target-AliasDies1,VSIR,V-Set Domain-Containing Immunoregulatory Receptor,DD1alpha,B7-H5,PD-1H,B7H5,GI24,Stress-induced secreted protein-1,PP2135,SISP1,UNQ730/PRO1412,V-type immunoglobulin domain-containing suppressor of T-cell activation,V-Set Immunoregulatory Receptor,V-Domain Ig Suppressor Of T Cell Activation,PDCD1 Homolog,C10orf54,Sisp-1,VISTA,Chromosome 10 Open Reading Frame 54,Stress Induced Secreted Protein 1,Platelet Receptor Gi24,Death Domain1alpha
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel8
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical

B7-H5 Molekülhintergrund

Platelet receptor Gi24, also known as B7-H5 and stress-induced secreted protein-1 (Sisp-1), is a protein that in humans is encoded by the C10orf54 gene, which contains 1 Ig-like (immunoglobulin-like) domain. As for C10orf54 gene, C10orf54 appears to positively interact with BMP-4, potentiating BMP signaling and the transition from an undifferentiated to a differentiated state on ESCs. Human C10orf54 undergoes proteolytic cleavage by MT1-MMP, generating a soluble 30 kDa extracellular fragment plus a 25-30 kDa membrane-bound fragment.

B7-H5 Molekülalias

B7-H5,SISP1,Gi24,VISTA

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
CA-170CA-170; AUPM-170Phase 3 ClinicalAurigeneCarcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours
Details
SolnerstotugSNS-101; SNS-VISTAPhase 2 ClinicalSensei Biotherapeutics IncBreast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
TrovostobartKVA-12123; KVA-12.1Phase 2 ClinicalGigaGen IncBreast Neoplasms; Carcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Uterine Neoplasms
Details
OnvatilimabCI-8993; JNJ-61610588Phase 1 ClinicalImmunext Inc, Johnson & Johnson Innovative MedicineNeoplasms; Solid tumours
Details
HMBD-002HMBD-002Phase 1 ClinicalHummingbird BioscienceCarcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
PMC-309PMC-309Phase 1 ClinicalPharmabcineNeoplasms; Solid tumours
Details
TBS-2025TBS-2025Phase 1 ClinicalKintara Therapeutics IncLeukemia, Myeloid, Acute
Details
LFD-200LFD-200Phase 1 ClinicalLifordi Immunotherapeutics IncArthritis, Rheumatoid
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns